So, a good IPO and the way they have priced it also, as you rightly said, that very reasonably priced and some money to be made on the table for the investors and in a pharma pack when we are seeing that most of the pharma packs are doing quite well and the way the segment which has been into Emcure is into, so all the front they have been firing at this point of time.
